Compare Inovio Pharmaceuticals Inc (INO) vs Prudential Financial Inc (PRU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Prudential Financial Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Prudential Financial Inc trades at $118.36 (market cap $40.97B). The key difference: Prudential Financial Inc is far larger — about 458.9× Inovio Pharmaceuticals Inc's market cap, and Prudential Financial Inc pays a 4.75% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | PRU | |
|---|---|---|
Market Cap | $89.27M | $40.97B |
Sector | Health | Financials |
52-Week High | $2.87 | $119.07 |
52-Week Low | $1.05 | $92.00 |
Enterprise Value | $60.28M | $68.03B |
Dividend Yield | — | 4.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Prudential Financial (PRU) trades at $118.04, down 0.87% on the day, showing mixed technical signals with a bullish overall trend but overbought RSI indicators. Fundamentally, the company demonstrates solid profitability with 5.5% net income margin and 11.08% ROE, though revenue declined from $70.7B in 2024 to $61.0B in 2025. Recent earnings show beats in Q3 2025 and Q1 2026, with Q2 2026 results expected August 4, 2026.
The stock presents a value opportunity with attractive valuation multiples (P/E 12.26, P/S 0.67) but faces headwinds from analyst skepticism (67.57% hold rating) and a consensus price target of $102.50 below current levels. Key risks include revenue volatility and high debt levels, while catalysts include retirement market growth and international expansion driving long-term earnings potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →
